However, NfL in blood and CSF cannot yet discriminate between MSA and PSP (Hansson et al., 2017); simultaneously, NfL is not a disease-specific biomarker, and its specificity is relatively low with increased NfL levels in other nervous system diseases (Palermo et al., 2020). Here, NEFL is linked to supranuclear palsy, progressive, 1.